IL1RN and juvenile idiopathic arthritis: Notably, the reduction effect of canakinumab on the concentrations of IL-1RA, IL-6, IL-18 and S100A12 in our cohort had been confirmed recently in a systemic juvenile idiopathic arthritis cohort.